Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy.

Angus, Lachlan; Leemaqz, Shalem; Ooi, Olivia; Cundill, Pauline; Silberstein, Nicholas; Locke, Peter; Zajac, Jeffrey D; Cheung, Ada S.

Afiliação

Angus L; Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.
Leemaqz S; Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia.
Ooi O; Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.
Cundill P; Equinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, Australia.
Silberstein N; Equinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, Australia.
Locke P; Equinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, Australia.
Zajac JD; Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.
Cheung AS; Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.

Endocr Connect ; 8(7): 935-940, 2019 Jul.

Article em En | MEDLINE | ID: mdl-31234145